Your browser doesn't support javascript.
loading
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: is PTEN predictive of response?
Lester, A; Rapkins, R; Nixdorf, S; Khasraw, M; McDonald, K.
Affiliation
  • Lester, A; University of NSW. Sydney. Australia
  • Rapkins, R; University of NSW. Sydney. Australia
  • Nixdorf, S; University of NSW. Sydney. Australia
  • Khasraw, M; University of Sydney. NHMRC Clinical Trials Centre. Sydney. Australia
  • McDonald, K; University of NSW. Sydney. Australia
Clin. transl. oncol. (Print) ; 19(3): 273-278, mar. 2017. ilus
Article in English | IBECS | ID: ibc-160182
Responsible library: ES1.1
Localization: BNCS
ABSTRACT
Glioblastoma (GBM) is fatal. The standard radiotherapy and chemotherapy (temozolomide) followed by an adjuvant phase of temozolomide provide patients with, on average, a 2.5 months benefit. New treatments that can improve sensitivity to the standard treatment are urgently needed. Herein, we review the mechanisms and utility of poly (ADP-ribose) polymerase inhibitors in combination with radiation therapy as a treatment option for GBM patients and the role of phosphatase and tensin homologue mutations as a biomarker of response (AU9
RESUMEN
No disponible
Subject(s)
Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Biomarkers / Biomarkers, Tumor / Glioblastoma / PTEN Phosphohydrolase / Chemoradiotherapy, Adjuvant Type of study: Prognostic study / Risk factors Limits: Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2017 Document type: Article Institution/Affiliation country: University of NSW/Australia / University of Sydney/Australia
Search on Google
Add to My VHL
Print
XML

Collection: National databases / Spain Database: IBECS Main subject: Biomarkers / Biomarkers, Tumor / Glioblastoma / PTEN Phosphohydrolase / Chemoradiotherapy, Adjuvant Type of study: Prognostic study / Risk factors Limits: Female / Humans / Male Language: English Journal: Clin. transl. oncol. (Print) Year: 2017 Document type: Article Institution/Affiliation country: University of NSW/Australia / University of Sydney/Australia